VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Thursday, January 8, 2026

Wide Moat Stocks Expansion-Stage Stocks Home My Collections

Stock Comparison

Brookfield Corporation vs Coloplast A/S

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Brookfield Corporation

BN · New York Stock Exchange

Market cap (USD)$109.6B

Gross margin (TTM)34.5%

Operating margin (TTM)24.1%

Net margin (TTM)1.3%

SectorFinancials

IndustryAsset Management

CountryCA

Data as of2026-01-05

Moat score

65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Brookfield Corporation's moat claims, evidence, and risks.

View BN analysis

Coloplast A/S

COLOB · Nasdaq Copenhagen

Market cap (USD)—

Gross margin (TTM)—

Operating margin (TTM)—

Net margin (TTM)—

SectorHealthcare

Industry—

CountryDK

Data as of2025-12-29

Moat score

77/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Coloplast A/S's moat claims, evidence, and risks.

View COLOB analysis

Comparison highlights

Moat score gap: Coloplast A/S leads (77 / 100 vs 65 / 100 for Brookfield Corporation).
Segment focus: Brookfield Corporation has 6 segments; Coloplast A/S has 5 segments (35.5% in Ostomy Care).
Moat breadth: Brookfield Corporation has 10 moat types across 5 domains; Coloplast A/S has 7 across 3.

Primary market context

Brookfield Corporation

Asset Management

Market

Alternative asset management (private markets: infrastructure, renewables, private equity, real estate, credit)

Geography

Global

Customer

Institutional investors and private wealth channels

Role

General partner (GP) / asset manager

Coloplast A/S

Ostomy Care

Market

Ostomy care products (bags, plates, supporting products)

Geography

Global

Customer

Healthcare providers and distributors; end-users are ostomy patients

Role

Medical device manufacturer (disposable consumables)

Revenue share

35.5%

Side-by-side metrics

Brookfield Corporation

Coloplast A/S

Ticker / Exchange

BN - New York Stock Exchange

COLOB - Nasdaq Copenhagen

Market cap (USD)

$109.6B

n/a

Gross margin (TTM)

34.5%

n/a

Operating margin (TTM)

24.1%

n/a

Net margin (TTM)

1.3%

n/a

Sector

Financials

Healthcare

Industry

Asset Management

n/a

HQ country

Primary segment

Asset Management

Ostomy Care

Market structure

Oligopoly

Market share

n/a

35%-40% (reported)

HHI estimate

n/a

Pricing power

Moderate

Moat score

65 / 100

77 / 100

Moat domains

Demand, Network, Financial, Supply, Legal

Demand, Legal, Supply

Last update

2026-01-05

2025-12-29

Moat coverage

Shared moat types

Brand Trust

Brookfield Corporation strengths

Long Term ContractsEcosystem ComplementsFloat PrepaymentCost Of Capital AdvantageCapex Knowhow ScalePermits Rights Of WayPhysical Network DensityOperational ExcellenceGeographic Natural

Coloplast A/S strengths

Installed Base ConsumablesTraining Org Change CostsReputation ReviewsCompliance AdvantageDesign In QualificationService Field Network

Segment mix

Brookfield Corporation segments

Full profile >

Asset Management

Oligopoly

n/a

Wealth Solutions (Insurance)

Competitive

n/a

Renewable Power and Transition

Competitive

n/a

Infrastructure

Oligopoly

n/a

Private Equity (Operating Businesses)

Competitive

n/a

Real Estate

Competitive

n/a

Coloplast A/S segments

Full profile >

Ostomy Care

Oligopoly

35.5%

Continence Care

Oligopoly

32.2%

Voice & Respiratory Care

Oligopoly

8.2%

Wound & Tissue Repair

Competitive

14.1%

Interventional Urology

Oligopoly

10%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.